Can selective serotonin reuptake inhibitors (SSRIs) decrease cortisol levels in patients with a history of anxiety or depression?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can SSRIs Decrease Cortisol Levels?

SSRIs have complex and variable effects on cortisol levels that depend on treatment duration and individual patient factors—they may initially increase cortisol responses but can reduce elevated baseline cortisol levels over extended treatment periods (3+ weeks) in patients with depression and anxiety.

Acute vs. Chronic Effects on Cortisol

The relationship between SSRIs and cortisol is not straightforward and changes over time:

Initial Treatment Phase (1-3 weeks)

  • SSRIs initially potentiate cortisol responses to serotonergic stimulation, with fluoxetine showing a large increase in cortisol response to 5-HTP after one week of treatment in healthy subjects 1
  • This early potentiation effect largely disappears by 3 weeks in healthy individuals but persists in depressed patients treated for 8 weeks 1
  • Fluoxetine specifically potentiates 5-HT receptor-mediated cortisol secretion through presynaptic mechanisms, unlike tricyclic antidepressants 2

Long-Term Treatment Effects (3+ weeks to 1 year)

  • After 3 weeks of SSRI treatment, cortisol levels decrease in depressed patients to levels comparable with healthy controls 3
  • The reduction in cortisol significantly correlates with improvement in depressive symptoms (r=0.52) and cognitive function 3
  • However, complete normalization of HPA axis function requires extended treatment—patients only reach partial reestablishment after 52 weeks of SSRI therapy 4
  • At 20 weeks, psychiatric remission occurs without cortisol changes, but by week 52, significant cortisol reduction (p<0.01) is finally observed 4

Differential Effects by SSRI Type

Not all antidepressants affect cortisol identically:

  • SSRIs as a class show modest effects on evening cortisol (slightly elevated, effect size d=0.04) and decreased cortisol suppression after dexamethasone (d=0.03) 5
  • Tricyclic antidepressants produce different cortisol patterns, showing a flattened cortisol awakening response (effect size d=0.34), which represents the strongest alteration among antidepressant subtypes 5
  • Fluoxetine demonstrates unique potentiation of cortisol responses not seen with tricyclics 2

Clinical Implications

When Cortisol Reduction Occurs

  • Cortisol reduction is associated with clinical improvement but is not immediate—expect meaningful decreases only after 3+ weeks of treatment 3
  • The cortisol-lowering effect appears most relevant in patients with elevated baseline cortisol (common in depression and anxiety disorders) 4

Monitoring Considerations

  • Improvement in cognitive domains (information processing speed, cognitive set-shifting) correlates with cortisol reduction (r=0.50 and r=0.34 respectively) 3
  • This suggests cortisol changes may serve as a biomarker for treatment response beyond just mood improvement 3

Important Caveats

  • SSRIs do not universally "cut down" cortisol—the effect depends on baseline HPA axis dysregulation 5, 4
  • In patients without elevated baseline cortisol, SSRIs may actually increase certain cortisol measures (evening levels, dexamethasone non-suppression) 5
  • The therapeutic mechanism of SSRIs likely involves complex HPA axis modulation rather than simple cortisol reduction 1, 2

Bottom Line for Clinical Practice

If your goal is cortisol reduction in a patient with documented hypercortisolism from depression or anxiety:

  • Expect a lag period of at least 3 weeks before cortisol levels begin to normalize 3
  • Full HPA axis normalization may require 6-12 months of continuous treatment 4
  • Monitor both clinical symptoms and cortisol levels as they improve in parallel but not identically 3
  • SSRIs are more appropriate than tricyclics if the primary concern is treating anxiety/depression rather than specifically targeting cortisol patterns 6

References

Research

Brain 5-HT neurotransmission during paroxetine treatment.

The British journal of psychiatry : the journal of mental science, 1998

Research

Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2008

Research

Antidepressant use and salivary cortisol in depressive and anxiety disorders.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2011

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.